HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ASENAPINE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for ASENAPINE SUBLINGUAL TABLETS.

ASENAPINE sublingual tablets Initial U.S. Approval: 2009

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Asenapine is not approved for the treatment of patients with dementia-related psychosis. (5.1, 5.2)

INDICATIONS AND USAGE Asenapine is an atypical antipsychotic indicated for (1): (1)

Acute monotherapy treatment of manic or mixed episodes, in pediatric patients 10 to 17 years of age (1)
 Adjunctive treatment to lithium or valoroate in the manual statement of the stat

DOSAGE AND ADMINISTRATION

	Starting Dose	Recommended Dose	Maximum Dose
Bipolar mania – pediatric patients (10 to 17 years): monotherapy (2.3)		2.5 to 10 mg sublingually twice daily	10 mg sublingually twice daily
Bipolar mania - adults: as an adjunct to lithium or valproate (2.3)		5 to 10 mg sublingually twice daily	10 mg sublingually twice daily

Do not swallow tablet. Asenapine sublingual tablets should be placed under the tongue and left to dissolve completely. The tablet will dissolve in saliva within seconds. Eating and drinking should be avoided for 10 minutes after administration. (2.1, 17) (2)

 CONTRAINDICATIONS
 Severe hepatic impairment (Child-Pugh C). (8.7, 12.3)
 Known hypersensitivity to asenapine, or to any components in the formulation. (4, 5.6, 17) (4)

WARNINGS AND PRECAUTIONS

factors: (5.9) • *QT Prolongation*: Increases in QT interval; avoid use with drugs that also increase the QT interval and in patients with risk factors for prolonged QT interval. (5.10) • *Seizures*: Use cautiously in patients with a history of seizures or with conditions that lower the seizure threshold. (5.12) • *Potential for Cognitive and Motor Impairment*: Use caution when operating machinery. (5.13) (5.12)

(5)

(6.1): (6)

Bipolar I Disorder Pediatric Patients (Monotherapy): somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, increased weight.

Bipolar I Disorder Adults (Adjunctive): somnolence, oral hypoesthesia. (6) (6)

To report SUSPECTED ADVERSE REACTIONS, contact Alembic Pharmaceuticals Limited at 1-866-210-9797 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. (6)

DRUG INTERACTIONS Antihypertensive Drugs: Asenapine may cause hypotension. (5.7, 7.1, 12.3) Paroxetine (CYP2D6 substrate and inhibitor): Reduce paroxetine by half when used in combination with asenapine. (7.1, 12.3) (7)

Organarcy: May cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure. (8.1)
 Pediatric Use: Safety and efficacy in the treatment of bipolar I disorder in patients less than 10 years of age have not been evaluated. (8.4)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 9/2021

FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS 1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

2.1 Administration Instructions 2.3 Bipolar I Disorder

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS 5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis

5.2 Cerebrovascular Adverse Events, Including Stroke, In Elderly Patients with

- Dementia-Related Psychosis 5.3 Neuroleptic Malignant Syndrome
- 5.4 Tardive Dyskinesia
- 5.5 Metabolic Changes

5.6 Hypersensitivity Reactions

5.7 Orthostatic Hypotension, Syncope, and Other Hemodynamic Effects

- 5.8 Falls
- 5.9 Leukopenia, Neutropenia, and Agranulocytosis
- 5.10 QT Prolongation
- 5.11 Hyperprolactinemia
- 5.12 Seizures
- 5.13 Potential for Cognitive and Motor Impairment
- 5.14 Body Temperature Regulation
- 5.15 Dysphagia
- 6 ADVERSE REACTIONS 6.1 Clinical Trials Experience
- 6.2 Postmarketing Experience
- **7 DRUG INTERACTIONS**
- 7.1 Drugs Having Clinically Important Drug Interactions with Asenapine 7.2 Drugs Having No Clinically Important Interactions with Asenapine
- **8 USE IN SPECIFIC POPULATIONS**
- 8.1 Pregnancy 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use 8.6 Renal Impairment
- 8.7 Hepatic Impairment
- 8.8 Other Specific Populations 9 DRUG ABUSE AND DEPENDENCE
- 9.1 Controlled Substance
- 9.2 Abuse 10 OVERDOSAGE
- 11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- **14 CLINICAL STUDIES** 14.2 Bipolar I Disorder

16 HOW SUPPLIED/STORAGE AND HANDLING

- 17 PATIENT COUNSELING INFORMATION
- Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Asenapine is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1, 5.2)].

1 INDICATIONS AND USAGE

Asenapine is indicated for

- Bipolar I disorder [see Clinical Studies (14.2)]
- · Acute monotherapy of manic or mixed episodes, in pediatric patients 10 to 17 years of

Adjunctive treatment to lithium or valproate in adults

2 DOSAGE AND ADMINISTRATION

2.1 Administration Instructions

Asenapine is a sublingual tablet. To ensure optimal absorption, patients should be instructed to place the tablet under the tongue and allow it to dissolve completely. The tablet will dissolve in saliva within seconds. Asenapine sublingual tablets should not be split, crushed, chewed, or swallowed [see Clinical Pharmacology (12.3)]. Patients should be instructed to not eat or drink for 10 minutes after administration [see Clinical Pharmacology (12.3)].

2.3 Bipolar I Disorder

Acute Treatment of Manic or Mixed Episodes:

Monotherapy in Pediatric Patients: The recommended dose of asenapine is 2.5 mg to 10 mg twice daily in pediatric patients 10 to 17 years of age, and dose may be adjusted for individual response and tolerability. The starting dose of asenapine is 2.5 mg twice daily. After 3 days, the dose can be increased to 5 mg twice daily, and from 5 mg to 10 mg twice daily after 3 additional days. Pediatric patients aged 10 to 17 years appear to be more sensitive to dystonia with initial dosing with asenapine when the recommended escalation schedule is not followed [see Use in Specific Populations (8.4)]. The safety of doses greater than 10 mg twice daily has not been evaluated in clinical trials [see Use in Specific Populations (8.4) and Clinical Pharmacology (12.3)].

Adjunctive Therapy in Adults: The recommended starting dose of asenapine is 5 mg twice daily when administered as adjunctive therapy with either lithium or valproate. Depending on the clinical response and tolerability in the individual patient, the dose can be increased to 10 mg twice daily. The safety of doses above 10 mg twice daily as adjunctive therapy with lithium or valproate has not been evaluated in clinical trials.

For patients on asenapine, used as adjunctive therapy with lithium or valproate, it is generally recommended that responding patients continue treatment beyond the acute episode.

3 DOSAGE FORMS AND STRENGTHS

2.5 mg: White to off white, round tablets debossed with 'L' on one side and '70' on the

other side.

5 mg: White to off white, round tablets debossed with "464" on one side and plain on

other side. ${\bf 10}\ {\rm mg:}$ White to off white round tablets debossed with "465" on one side and plain on other side.

4 CONTRAINDICATIONS

Asenapine is contraindicated in patients with:

- Severe hepatic impairment (Child-Pugh C) [see Specific Populations (8.7), Clinical Pharmacology (12.3)].
- A history of hypersensitivity reactions to asenapine. Reactions have included anaphylaxis, angioedema, hypotension, tachycardia, swollen tongue, dyspnea, wheezing and rash [see Warnings and Precautions (5.6), Adverse Reactions (6)].

5 WARNINGS AND PRECAUTIONS

5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drugtreated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group.

Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Asenapine is not approved for the treatment of patients with dementia-related psychosis [see Boxed Warning and Warnings and Precautions (5.2)].

5.2 Cerebrovascular Adverse Events, Including Stroke, In Elderly Patients with Dementia-Related Psychosis

In placebo-controlled trials in elderly subjects with dementia, patients randomized to risperidone, aripiprazole, and olanzapine had a higher incidence of stroke and transient ischemic attack, including fatal stroke. Asenapine is not approved for the treatment of patients with dementia-related psychosis [see Boxed Warning and Warnings and Precautions (5.1)].

5.3 Neuroleptic Malignant Syndrome

A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, delirium, and autonomic instability. Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. If NMS is suspected, immediately discontinue asenapine and provide intensive symptomatic treatment and monitoring.

5.4 Tardive Dyskinesia

Tardive dyskinesia, a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements, may develop in patients treated with antipsychotic drugs, including asenapine. The risk appears to be highest among the elderly, especially elderly women, but it is not possible to predict which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown.

The risk of tardive dyskinesia and the likelihood that it will become irreversible increase with the duration of treatment and the cumulative dose. The syndrome can develop after a relatively brief treatment period, even at low doses. It may also occur after discontinuation of treatment.

There is no known treatment for tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is discontinued. Antipsychotic treatment itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome, possibly masking the underlying process. The effect that symptomatic suppression has upon the long-term course of tardive dyskinesia is unknown.

Given these considerations, asenapine should be prescribed in a manner most likely to reduce the risk of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients: 1) who suffer from a chronic illness that is known to respond to antipsychotic drugs; and 2) for whom alternative, effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, use the lowest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. Periodically reassess the need for continued treatment.

If signs and symptoms of TD appear in a patient on asenapine, drug discontinuation should be considered. However, some patients may require treatment with asenapine despite the presence of the syndrome.

5.5 Metabolic Changes

Atypical antipsychotic drugs, including asenapine, have caused metabolic changes, including hyperglycemia, diabetes mellitus, dyslipidemia, and body weight gain. Although all of the drugs in the class to date have been shown to produce some metabolic changes, each drug has its own specific risk profile.

Hyperglycemia and Diabetes Mellitus

Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. There have been reports of hyperglycemia in patients treated with asenapine. Assess fasting plasma glucose before or soon after initiation of antipsychotic medication, and monitor periodically during long-term treatment. $\mathit{Adult Patients:}$ Pooled data from the short-term placebo-controlled bipolar mania trials are presented in Table 1.

Table 1: Changes in Fasting Glucose in Adult Patients

	Bipolar I Disorder (3-weeks)						
			Asenapine	•			
	Placebo	5 mg twice daily	10 mg twice daily	5 mg or 10 mg twice daily [†]			
Mean Change from Baseline in Fasting Glucose at Endpoint							
Change from Baseline	0	4.1	3.5	1.7			
(mg/dL) (N*)	(174)	(84)	(81)	(321)			
Proportion of I	Patients with	Shifts from B	aseline to En	dpoint			
Normal to High	2.4%	0%	1.7%	1.8%			
<100 to ≥126 mg/dL (n/N**)	(3/126)	(0/53)	(1/60)	(4/224)			
Borderline to High ≥100 and <126 to ≥126 mg/dL (n/N ^{**})	0% (0/39)	12.5% (3/24)	15.8% (3/19)	12.8% (10/78)			

 N^* = Number of patients who had assessments at both Baseline and Endpoint.

 $\mathbf{N}^{**}=\mathbf{N}\mathbf{u}\mathbf{m}\mathbf{b}\mathbf{r}$ of patients at risk at Baseline with assessments at both Baseline and Endpoint.

 † Includes patients treated with flexible dose of as enapine 5 mg or 10 mg twice daily (N=379).

In a 52-week, double-blind, comparator-controlled trial, the mean increase from baseline of fasting glucose was 2.4 mg/dL.

Pediatric Patients: Data from the short-term, placebo-controlled trial in pediatric patients with bipolar I disorder are shown in **Table 2**.

Table 2: Changes in Fasting Glucose in Pediatric Subjects

	Bipolar I Disorder (3-weeks)						
	Placebo	Asenapine10 mg twice daily					
Mean	Change from I	Baseline in Fastin	g Glucose to En	idpoint			
Change from Baseline (mg/dL) (N*)	-2.24 (56)	1.43 (51)	-0.45 (57)	0.34 (52)			
Propor	Proportion of Subjects with Shifts from Baseline to Endpoint						
Normal to High >45 & <100 to ≥126 mg/dL	0%	0%	1.8%	0%			
(n/N*)	(0/56)	(0/51)	(1/57)	(0/52)			

 N^{\ast} = Number of subjects who had assessments at both Baseline and Endpoint

Dyslipidemia

Atypical antipsychotics cause adverse alterations in lipids. Before or soon after initiation of antipsychotic medication, obtain a fasting lipid profile at baseline and monitor periodically during treatment.

Adult Patients: Pooled data from the short-term, placebo-controlled bipolar mania trials are presented in $\ensuremath{\text{Table 3.}}$

Table 3: Changes in Lipids in Adult Patients

Bipolar I Disorder (3-weeks)				
	Asenapine			
Placebo	5 mg twice	10 mg	5 mg or 10 mg twice	

		uany	LWICE Gally	daily [†]				
Mean Change from Baseline (mg/dL)								
Total cholesterol (N*)	-1.6 (278)	-1.6 (108)	-4.7 (95)	-0.5 (525)				
LDL (N [*])	1.4 (271)	-2.5 (101)	-4.1 (94)	-0.3 (499)				
HDL (N*)	0.2 (278)	0.1 (108)	0.7 (95)	0.7 (525)				
Fasting triglycerides (N*)	-16.9 (222)	3.9 (89)	-8.5 (85)	-3 (411)				
Proportion	of Patients w	ith Shifts from	n Baseline to En	dpoint				
Total cholesterol Normal to High <200 to \geq 240 (mg/dL) (n/N [*])	1.2 (2/174)	3 (2/66)	0 (0/63)	2.1 (7/333)				
LDL Normal to High <100 to ≥160 (mg/dL) (n/N*)	1.9 (2/108)	2.4 (1/41)	0 (0/41)	0.5 (1/223)				
HDL Normal to Low \geq 40 to <40 (mg/dL) (n/N [*])	7.4 (16/215)	4.1 (4/97)	5.1 (4/78)	7 (29/417)				
Fasting triglycerides Normal to High <150 to ≥200 (mg/dL) (n/N*)	4.6 (7/153)	8.2 (5/61)	1.6 (1/64)	6.2 (17/273)				

 N^{\ast} = Number of subjects who had assessments at both Baseline and Endpoint. † Includes patients treated with flexible dose of asenapine 5 mg or 10 mg twice daily (N=379).

In short-term, placebo-controlled bipolar mania trials, the proportion of patients with total cholesterol elevations \geq 240 mg/dL (at Endpoint) was 7.8% for asenapine-treated patients versus 7.9% for placebo-treated patients. The proportion of patients with elevations in triglycerides \geq 200 mg/dL (at Endpoint) was 13.1% for asenapine-treated patients versus 8.6% for placebo-treated patients.

Pediatric Patients: Data from the short-term, placebo-controlled bipolar mania trial are presented in **Table 4**.

Table 4: Changes in Fasting Lipids in Pediatric Subjects

		Bipolar I Disor	rder (3-week	s)
	Placebo	Asenapine2.5 mg twice daily	Asenapine5 mg twice daily	Asenapine10 mg twice daily
	Mean Char	nge from Baseline	e (mg/dL)	
Total Fasting cholesterol (N*)	-2.3 (57)	3.7 (50)	7.2 (57)	9.3 (52)
Fasting LDL (N [*])	-2.5 (57)	-0.2 (50)	3 (57)	4.9 (51)
Fasting HDL (N [*])	1.6 (57)	2.3 (50)	1.5 (57)	1.7 (52)
Fasting triglycerides (N [*])	-6.6 (57)	8.7 (50)	13.4 (57)	14.7 (52)
Proportion	of Subjects	with Shifts from	Baseline to En	dpoint
Total Fasting cholesterol Normal to High <170 to > = 200 (mg/dL) (n/N*)	1.8% (1/57)	0% (0/50)	1.8% (1/57)	0% (0/52)
Fasting LDL Normal to High <110 to $> = 130(n/N^*)$	1.8% (1/57)	2% (1/50)	1.8% (1/57)	0% (0/51)
Fasting HDL Normal to Low \geq 40 to <40 (mg/dL) (n/N [*])	3.5% (2/57)	6% (3/50)	3.5% (2/57)	9.6% (5/52)

(mg/dL) (n/N*)	Fasting triglycerides Normal to High <150 to \geq 200 (mg/dL) (n/N [*])	0% (0/57)	4% (2/50)	3.5% (2/57)	1.9% (1/52)
-------------------	--	--------------	--------------	----------------	----------------

 N^{\ast} = Number of patients who had assessments at both Baseline and Endpoint Weight Gain

Weight gain has been observed in patients treated with atypical antipsychotics, including asenapine. Monitor weight at baseline and frequently thereafter.

Adult Patients: Pooled data on mean changes in body weight and the proportion of subjects meeting a weight gain criterion of \geq 7% of body weight from the short-term, placebo-controlled bipolar mania trials are presented in **Table 5.**

Table 5: Change in Body Weight in Adult Patients from Baseline

	Bipolar I Disorder (3-weeks)						
		Asenapine					
	Placebo	5 mg twice daily	10 mg twice daily	5 mg or 10 mg twice daily [†]			
Change from Baseline (kg) (N*)	0.2 (288)	1.4 (110)	1.3 (98)	1.3 (544)			
Proportion of Patients with a \geq 7% Increase in Body Weight							
% with ≥7% increase in body weight	0.4%	6.4%	1%	5.5%			

 N^* = Number of subjects who had assessments at both Baseline and Endpoint. [†] Includes patients treated with flexible dose of asenapine 5 mg or 10 mg twice daily (n=379).

Adult Patients: In a 52-week, double-blind, comparator-controlled adult trial, the mean weight gain from baseline was 0.9 kg. The proportion of patients with a \geq 7% increase in body weight (at Endpoint) was 14.7%. **Table 6** provides the mean weight change from baseline and the proportion of patients with a weight gain of \geq 7% categorized by Body Mass Index (BMI) at baseline.

Table 6: Weight Change Results Categorized by BMI at Baseline: Comparator-Controlled 52-Week Study in Adult Patients

	BMI <23 Asenapine N=295	BMI 23 - ≤27 Asenapine N=290	BMI >27 Asenapine N=302
Mean change from Baseline (kg)	1.7	1	0
% with ≥7% increase in body weight	22%	13%	9%

Pediatric Patients: Data on mean changes in body weight and the proportion of pediatric patients meeting a weight gain criterion of \geq 7% of body weight from the short-term, placebo-controlled bipolar mania trial are presented in **Table 7**. To adjust for normal growth, z-scores were derived (measured in standard deviations [SD]), which normalize for the natural growth of pediatric patients by comparisons to age-and sex-matched population standards.

The distance of a z-score from 0 represents the distance of a percentile from the median, measured in standard deviations (SD). After adjusting for age and sex, the mean change from baseline to endpoint in weight z-score for asenapine 2.5 mg, 5 mg, and 10 mg twice daily, was 0.11, 0.08 and 0.09 SD versus 0.02 SD for placebo, respectively.

When treating pediatric patients, weight gain should be monitored and assessed against that expected for normal growth.

Table 7: Change in Body Weight in Pediatric Subjects from Baseline

	Placebo	Asenapine 2.5 mg twice daily	Asenapine 5 mg twice daily	Asenapine 10 mg twice daily	
Mean	Change from E	Baseline in Fastin	ig Glucose to En	idpoint	
Change from Baseline (kg) (N [*])	0.5 (89)	1.7 (92)	1.6 (90)	1.4 (87)	
Proportion of Subjects with a ≥7% increase in Body Weight					
% with ≥7% increase in body weight	1.1%	12%	8.9%	8%	

 $N^* = Number of subjects who had assessments at both Baseline and Endpoint.$

5.6 Hypersensitivity Reactions

Hypersensitivity reactions have been observed in patients treated with asenapine. In several cases, these reactions occurred after the first dose. These hypersensitivity reactions included: anaphylaxis, angioedema, hypotension, tachycardia, swollen tongue, dyspnea, wheezing and rash.

5.7 Orthostatic Hypotension, Syncope, and Other Hemodynamic Effects

Atypical antipsychotics cause orthostatic hypotension and syncope. Generally, the risk is greatest during initial dose titration and when increasing the dose. In short-term bipolar mania adult trials, syncope was reported in 0.2% (1/620) of patients treated with therapeutic doses (5 mg or 10 mg twice daily) of asenapine, compared to 0% (0/329) of patients treated with placebo. During adult pre-marketing clinical trials with asenapine, including long-term trials without comparison to placebo, syncope was reported in 0.6% (1/1953) of patients treated with asenapine. In a 3-week, bipolar mania pediatric trial, syncope was reported in 1% (1/104) of patients treated with asenapine 5 mg twice daily, 1% (1/99) of patients treated with asenapine 5 mg twice daily, and 0% (0/99) for patients treated with asenapine 10 mg twice daily compared to 0% (0/101) for patients treated with placebo.

Orthostatic vital signs should be monitored in patients who are vulnerable hypotension (elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications, patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), and patients with cerebrovascular disease. Asenapine should be used cautiously when treating patients who receive treatment with other drugs that can induce hypotension, bradycardia, respiratory or central nervous system depression [see Drug Interactions (7.1)]. Monitoring of orthostatic vital signs should be considered in all such patients, and a dose reduction should be considered if hypotension occurs.

5.8 Falls

Asenapine may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls and, consequently, fractures or other injuries. For patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy.

5.9 Leukopenia, Neutropenia, and Agranulocytosis

In clinical trial and postmarketing experience, leukopenia and neutropenia have been reported temporally related to antipsychotic agents, including asenapine. Agranulocytosis (including fatal cases) has been reported with other agents in the class.

Possible risk factors for leukopenia/neutropenia include pre-existing low white blood cell count (WBC) or absolute neutrophil count (ANC) and history of drug induced leukopenia/neutropenia. In patients with a pre-existing low WBC or ANC or a history of drug-induced leukopenia or neutropenia, perform a complete blood count (CBC) during the first few months of therapy. In such patients, consider discontinuation of asenapine at the first sign of a clinically significant decline in WBC in the absence of other causative factors.

Monitor patients with clinically significant neutropenia for fever or other symptoms or signs of infection and treat promptly if such symptoms or signs occur. Discontinue asenapine in patients with severe neutropenia (absolute neutrophil count <1000/mm³) and follow their WBC until recovery.

5.10 QT Prolongation

The effects of asenapine on the QT/QTc interval were evaluated in a dedicated adult QT study. This trial involved asenapine doses of 5 mg, 10 mg, 15 mg, and 20 mg twice daily, and placebo, and was conducted in 151 clinically stable patients with electrocardiographic assessments throughout the dosing interval at baseline and steady state. At these doses, asenapine was associated with increases in QTc interval ranging from 2 to 5 msec compared to placebo. No patients treated with asenapine experienced QTc increases \geq 60 msec from baseline measurements, nor did any patient experience a QTc of \geq 500 msec.

Electrocardiogram (ECG) measurements were taken at various time points during the asenapine clinical trial program (5 mg or 10 mg twice daily doses). Post-baseline QT prolongations exceeding 500 msec were reported at comparable rates for asenapine and placebo in these short-term trials. There were no reports of Torsade de Pointes or any other adverse reactions associated with delayed ventricular repolarization.

The use of asenapine should be avoided in combination with other drugs known to prolong QTc including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and antibiotics (e.g., gatifloxacin, moxifloxacin). Asenapine should also be avoided in patients with a history of cardiac arrhythmias and in other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death in association with the use of drugs that prolong the QTc interval, including bradycardia; hypokalemia or hypomagnesemia; and presence of congenital prolongation of the QT interval.

5.11 Hyperprolactinemia

Like other drugs that antagonize dopamine D₂ receptors, asenapine can elevate prolactin levels, and the elevation can persist during chronic administration. Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactinelevating compounds. Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male subjects. In asenapine adult pre-marketing clinical trials, the incidences of adverse events related to abnormal prolactin levels were 0.4% versus 0% for placebo.

In a 3-week, bipolar mania pediatric trial, the incidence of adverse events related to abnormal prolactin levels were 0% in the asenapine 2.5 mg twice daily treatment group, 2% in the asenapine 5 mg twice daily treatment group, and 1% in the asenapine 10 mg twice daily treatment group versus to 1% for patients treated with placebo [see Adverse Reactions (6.1)].

Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin-dependent *in vitro*, a factor of potential importance if the prescription of these drugs is considered in a patient with previously-detected breast cancer. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans, but the available evidence is too limited to be conclusive.

5.12 Seizures

Seizures were reported in 0% and 0.3% (0/572, 1/379) of adult patients treated with doses of 5 mg and 10 mg twice daily of asenapine, respectively, compared to 0% (0/203) of patients treated with placebo in pre-marketing short-term bipolar mania trials. During adult pre-marketing clinical trials with asenapine, including long-term trials without comparison to placebo, seizures were reported in 0.3% (5/1953) of patients treated with asenapine. There were no reports of seizures in pediatric patients treated with asenapine in a 3-week-term, bipolar mania trial.

As with other antipsychotic drugs, asenapine should be used with caution in patients with a history of seizures or with conditions that potentially lower the seizure threshold. Conditions that lower the seizure threshold may be more prevalent in patients 65 years or older.

5.13 Potential for Cognitive and Motor Impairment

Somnolence was reported in patients treated with asenapine. It was usually transient with the highest incidence reported during the first week of treatment. In short-term, placebo-controlled bipolar mania adult trials of therapeutic doses (5 to 10 mg twice daily), somnolence was reported in 23% (145/620) of patients on asenapine compared to 5% (18/329) of placebo patients. In another study, somnolence occurred at a lower rate in the 5 mg twice daily dose 20% (24/122) versus the 10 mg twice daily dose 26% (31/119) compared to 4% (5/126) in placebo patients. During adult pre-marketing clinical trials with asenapine, including long-term trials without comparison to placebo, somnolence was reported in 18% (358/1953) of patients treated with asenapine. Somnolence led to discontinuation in 0.6% (12/1953) of patients in short-term, placebo-

In a 3-week, placebo-controlled, bipolar I pediatric trial, the incidence of somnolence (including sedation and hypersomnia) for placebo, asenapine 2.5 mg twice daily, 5 mg twice daily, and 10 mg twice daily, was 12% (12/101), 46% (48/104), 53% (52/99), and 49% (49/99), respectively. Somnolence led to discontinuation in 0%, 3%, 1%, and 2% of patients treated with placebo, and asenapine 2.5 mg twice daily, 5 mg twice daily, and 10 mg twice daily, and 2% of patients treated with placebo, and asenapine 2.5 mg twice daily, 5 mg twice daily, and 10 mg twice daily, respectively.

Patients should be cautioned about operating hazardous machinery, including motor vehicles, until they are reasonably certain that asenapine therapy does not affect them adversely.

5.14 Body Temperature Regulation

Atypical antipsychotics may disrupt the body's ability to reduce core body temperature. In the pre-marketing short-term placebo-controlled trials for acute bipolar I disorder and another indication, the incidence of adverse reactions suggestive of body temperature increases was low ($\leq 1\%$) and comparable to placebo (0%). During pre-marketing clinical trials with asenapine, including long-term trials without comparison to placebo, the incidence of adverse reactions suggestive of body temperature increases (pyrexia and feeling hot) was $\leq 1\%$.

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use asenapine with caution in patient who may experience these conditions.

5.15 Dysphagia

Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Dysphagia has been reported with asenapine. Asenapine and other antipsychotic drugs should be used cautiously in patients at risk for aspiration.

6 ADVERSE REACTIONS

The following adverse reactions are discussed in more detail in other sections of the labeling:

- Use in Elderly Patients with Dementia-Related Psychosis [see Boxed Warning and Warnings and Precautions (5.1 and 5.2)]
- Neuroleptic Malignant Syndrome [see Warnings and Precautions (5.3)]

- Tardive Dyskinesia [see Warnings and Precautions (5.4)]
- Metabolic Changes [see Warnings and Precautions (5.5)]
- Hypersensitivity Reactions [see Contraindications, Warnings and Precautions (5.6)] Orthostatic Hypotension, Syncope, and other Hemodynamic Effects [see Warnings]
- and Precautions (5.7)] • Falls [see Warnings and Precautions (5.8)]
- Leukopenia, Neutropenia, and Agranulocytosis [see Warnings and Precautions (5.9)]
- QT Interval Prolongation [see Warnings and Precautions (5.10)]
- Hyperprolactinemia [see Warnings and Precautions (5.11)] • Seizures [see Warnings and Precautions (5.12)]
- Potential for Cognitive and Motor Impairment [see Warnings and Precautions (5.13)] • Body Temperature Regulation [see Warnings and Precautions (5.14)]
- Dysphagia [see Warnings and Precautions (5.15)]

The most common adverse reactions (\geq 5% and at least twice the rate of placebo) reported during the adjunctive therapy trial in bipolar I disorder in adults were somnolence and oral hypoesthesia. The rates were lower at the 5 mg twice daily dose than the 10 mg twice daily dose for all of these most common adverse reactions.

The adult information below is derived from a clinical trial database for asenapine consisting of over 5355 patients and/or healthy subjects exposed to one or more sublingual doses of asenapine. A total of 1427 asenapine-treated patients were treated for at least 24 weeks and 785 asenapine-treated patients had at least 52 weeks of exposure at therapeutic doses

In a 3-week monotherapy trial, the most common adverse reactions (\geq 5% and at least twice the rate of placebo) reported in pediatric patients with bipolar I disorder treated with asenapine were somnolence, dizziness, dysgeusia, oral hyporethesia, nausea, increased appetite, fatigue, and increased weight. No new major safety findings were reported from a 50-week, open-label, uncontrolled safety trial.

A total of 651 pediatric patients were treated with asenapine. Of these patients, 352 pediatric patients were treated with asenapine for at least 180 days and 58 pediatric patients treated with asenapine had at least 1 year of exposure. The safety of asenapine was evaluated in 403 pediatric patients with bipolar I disorder who participated in a 3-week, placebo-controlled, double-blind trial, of whom 302 patients received asenapine at fixed doses ranging from 2.5 mg to 10 mg twice daily.

The stated frequencies of adverse reactions represent the proportion of individuals who experienced a treatment-emergent adverse event of the type listed. A reaction was considered treatment emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation.

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Monotherapy in Pediatric Patients with Bipolar Mania: The following findings are based on a 3-week , placebo-controlled trial for bipolar mania in which asenapine was administered at doses of 2.5 mg, 5 mg, or 10 mg twice daily.

Adverse Reactions Leading to Discontinuation of Treatment: A total of 6.7% (7/104) of patients treated with asenapine 2.5 mg twice daily, 5.1% (5/99) of patients treated with asenapine 5 mg twice daily, and 5.1% (5/99) of patients treated with asenapine 10 mg twice daily discontinued treatment due to adverse reactions compared to 4% (4/101) on placebo. The most common adverse reactions that led to discontinuation in pediatric patients treated with asenapine (rates at least 2% in any asenapine arm and at least twice the placebo rate) were somnolence (3% in the 2.5 mg twice daily group, 1% in the 5 mg twice daily group, and 2% in the 10 mg twice daily group), abdominal pain (2% in the 10 mg twice daily group), and nausea (2% in the 10 mg twice daily group) No placebo-treated patients dropped out for these events.

Adverse Reactions Occurring with asenapine at an Incidence of 2% or More in asenapine-treated Bipolar I Patients: Adverse reactions associated with the use of as enapsine (incidence of $\geq 2\%$ in any as enapsine dose group and greater than placebo) that occurred during acute therapy are shown in **Table 10**.

Table 10: Adverse Reactions Reported in 2% or More of Pediatric Patients (Ages 10 to 17 Years) in Any Asenapine Dose Group and Which Occurred at Greater Incidence Than in the Placebo Group in a 3-Week Bipolar Mania Trial

System Organ Class / AE Preferred Term	Placebo		Asenapine 5 mg twice daily	Asenapine 10 mg twice daily	All Asenapine 2.5, 5, and 10 mg				
	N=101 %	N=104 %	N=99 %	N=99 %	N=302 %				
Cardiac Disorders									
Tachycardia ¹	0	3	0	1	1				
Gastrointestinal	Gastrointestinal Disorders								
Oral hypoesthesia ²	4	25	25	30	27				
Nausea	3	6	6	6	6				
Vomiting	3	4	4	4	4				
Abdominal pain ³	7	9	3	5	6				

Glossodynia	0	0	2	0	1
General Disorde	rs and A	dministrati	ve Site Diso	orders	
Fatique ⁴	5	4	8	14	9
Irritability	1	1	1	2	1
	-	_	_	-	I
Injury, Poisoning			-		
Muscle strain	0	0	0	2	1
Investigations					
Increased weight	0	6	2	2	3
Hyperinsulinemia ⁵	0	1	3	1	2
ALT increased	0	0	0	2	1
AST increased	0	0	0	2	1
Metabolism and	Nutritior	Disorders			
Increased appetite	2	10	9	6	8
Dehydration	1	0	2	0	1
Musculoskeletal	and Con	nective Tis	sue Disord	ers	
Myalgia	0	0	2	1	1
Nervous System					
Somnolence ⁶	12	46	52	49	49
			53		
Headache	6	8	11	9	9
Dizziness	3	6	10	5	7
Dysgeusia	2	4	5	9	6
Akathisia	0	2	2	1	2
Parkinsonism	0	1	0	2	1
Psychiatric Diso	rders				
Insomnia	3	3	4	3	3
Suicidal ideation	1	4	1	3	3
Anger	0	0	0	2	1
Reproductive Sy	stem an	d Breast D	isorders		
Dysmenorrhea	1	0	2	0	1
Respiratory, Tho	racic. ar	nd Mediasti	nal Disorde	ers	
					1
Oropharyngeal pain	2	0	3	1	1
Nasal congestion	1	0	2	0	1
Dyspnea	0	0	2	0	1
Skin and Subcut	aneous 1	rissue Diso	rders		1
Rash	1	0	1	2	1
	-	5	-	2	-

¹ Includes the preferred terms tachycardia and heart rate increased.

² Includes the preferred terms oral hypoesthesia, oral paresthesia, and oral dysesthesia.
³ Includes the preferred terms abdominal pain, abdominal pain upper, abdominal pain lower, and abdominal discomfort.

⁴ Includes the preferred terms fatigue and lethargy.

⁵ Includes the preferred terms hyperinsulinemia and blood insulin increased.

⁶ Includes the preferred terms somnolence, sedation, and hypersomnia.

<u>Dose-Related Adverse Reactions:</u> In the short term pediatric bipolar I trial the incidence of fatigue appeared to be dose-related (see **Table 10**).

Adjunctive Therapy in Adult Patients with Bipolar Mania: The following findings are based on a 12 week placebo-controlled trial (with a 3 week efficacy endpoint) in adult patients with bipolar mania in which sublingual asenapine was administered in doses of 5 mg or 10 mg twice daily as adjunctive therapy with lithium or valproate.

Adverse Reactions Associated with Discontinuation of Treatment: Approximately 16% (25/158) of asenapine-treated patients discontinued treatment due to an adverse reaction, compared with about 11% (18/166) on placebo. The most common adverse reactions associated with discontinuation in subjects treated with asenapine (rates at least 1% and at least twice the placebo rate) were depression (2.5%), suicidal ideation (2.5%), bipolar I disorder (1.9%), insomnia (1.9%) and depressive symptoms (1.3%).

Adverse Reactions Occurring at an Incidence of 2% or More Among Asenapine-Treated (Adjunctive) Bipolar I Patients: Adverse reactions associated with the use of asenapine (incidence of 2% or greater, rounded to the nearest percent, and asenapine incidence greater than placebo) that occurred during acute adjunctive therapy at 3 weeks, a time when most of the patients were still participating in the trial, are shown in **Table 11**.

Table 11: Adverse Reactions Reported in 2% or More of Adult Patients In Any Asenapine-Dose Group and Which Occurred at Greater Incidence Than in the Placebo Group at 3 Weeks in Adjunctive Bipolar Mania Trials

System Organ Class/Preferred Term	Placebo N=166 %	Asenapine 5 mg or 10 mg twice daily* N=158 %						
Gastrointestinal disorders								
Dyspepsia	2	3						
Oral hypoesthesia	0	5						
General disorders								
Fatigue	2	4						
Edema peripheral	<1	3						
Investigations								
Increased weight	0	3						
Nervous system disorders								
Dizziness	2	4						
Other extrapyramidal symptoms (excluding akathisia) [†]	5	6						
Somnolence [‡]	10	22						
Psychiatric disorders								
Insomnia	8	10						
Vascular disorders								
Hypertension	<1	3						

* Asenapine 5 mg to 10 mg twice daily with flexible dosing.

 † Extrapyramidal symptoms included: dystonia, parkinsonism, oculogyration, and tremor (excluding akathisia).

[‡] Somnolence includes the following events: somnolence and sedation.

Dystonia: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups [see Dosage and Administration (2.3), Use in Specific Populations (8.4), and Clinical Pharmacology (12.3)].

Extrapyramidal Symptoms: In the short-term, placebo-controlled bipolar mania adult trials, data was objectively collected on the Simpson Angus Rating Scale for extrapyramidal symptoms (EPS), the Barnes Akathisia Scale (for akathisia) and the Assessments of Involuntary Movement Scales (for dyskinesias). The mean change from baseline for the all-asenapine 5 mg or 10 mg twice daily treated group was comparable to placebo in each of the rating scale scores.

In short-term placebo-controlled bipolar mania adult trials, the incidence of EPS-related events, excluding events related to akathisia, for asenapine-treated patients was 8% versus 4% for placebo; and the incidence of akathisia-related events for asenapine-treated patients was 7% versus 3% for placebo. The incidence rates of all EPS events (including akathisia) were lower at the 5 mg twice daily dose (11% of N=122) than the 10 mg twice daily dose (25% of N=119) in another study.

In a 3-week, placebo-controlled pediatric trial with bipolar I disorder, the incidences of EPS-related events, excluding events related to akathisia, were 4%, 3%, and 5% for patients treated with asenapine 2.5 mg, 5 mg, and 10 mg twice daily, respectively, as compared to 3% for placebo-treated patients. EPS-related events include: bradykinesia, dyskinesia, dyskonia, oromandibular dystonia, muscle contractions involuntary, muscle twitching, musculoskeletal stiffness, parkinsonism, protrusion tongue, resting tremor, and tremor.

For events of akathisia, incidences were 2%, 2%, and 1% for pediatric patients treated with asenapine 2.5 mg, 5 mg, and 10 mg twice daily, respectively, as compared to 0% for placebo-treated patients.

Other Findings: Oral hypoesthesia and/or oral paresthesia may occur directly after administration of asenapine and usually resolves within 1 hour.

Laboratory Test Abnormalities:

<u>Transaminases</u>: Transient elevations in serum transaminases (primarily ALT) in the shortterm bipolar mania adult trials were more common in treated patients. In short-term, placebo-controlled bipolar mania adult trials, the mean increase in transaminase levels for asenapine-treated patients was 6.1 units/L compared to a decrease of 3.9 units/L in placebo-treated patients. The proportion of patients with transaminase elevations \geq 3 times upper limit of normal (ULN) (at Endpoint) was 2.1% for asenapine-treated patients versus 0.7% for placebo-treated patients. The incidence rate of transaminase elevations \geq 3 times ULN is 3% of N=95 for 10 mg twice daily dose, and 0% of N=108 for the 5 mg twice daily dose and 0% of N=115 for placebo in another study.

In a 52-week, double-blind, comparator-controlled trial that included primarily adult patients, the mean increase from baseline of ALT was 1.7 units/L.

In a 3-week, placebo-controlled pediatric trial with bipolar I disorder, transient elevations in serum transaminases (primarily ALT) were more common in treated patients. The proportion of pediatric patients with ALT elevations \geq 3 times upper limit of normal (ULN) was 2.4% for patients treated with asenapine 10 mg twice daily versus none for the other asenapine dose groups and placebo-treated patients.

<u>Prolactin</u>: In short-term, placebo-controlled bipolar mania adult trials, the mean increase in prolactin levels was 6.7 ng/mL for asenapine-treated patients compared to a decrease of 1 ng/mL for placebo-treated patients. The proportion of patients with prolactin elevations \geq 4 times ULN (at Endpoint) were 2% for asenapine-treated patients versus 0.8% for placebo-treated patients.

In a long-term (52-week), double-blind, comparator-controlled adult trial, the mean decrease in prolactin from baseline for asenapine-treated patients was 26.9 ng/mL.

In a 3-week, placebo-controlled pediatric trial with bipolar I disorder, the mean increases (at Endpoint) in prolactin levels were 3.2 ng/mL for patients treated with asenapine 2.5 mg twice daily, 2.1 ng/mL for patients treated with asenapine 5 mg twice daily, and 6.4 ng/mL for patients treated with asenapine 10 mg twice daily compared to an increase of 2.5 ng/mL for placebo-treated patients. There were no reports of prolactin elevations \geq 4 times ULN (at Endpoint) for patients treated with asenapine or placebo. Galactorrhea or dysmenorrhea were reported in 0% of patients treated with asenapine 2.5 mg twice daily, 2% of patients treated with asenapine 5 mg twice daily, and 1% of patients treated with asenapine 10 mg twice daily, and 1% of patients. There were no reports of gynecomastia in this trial.

<u>Creatine Kinase (CK)</u>: The proportion of adult patients with CK elevations >3 times ULN at any time were 6.4% and 11.1% for patients treated with asenapine 5 mg twice daily and 10 mg twice daily, respectively, as compared to 6.7% for placebo-treated patients in pre-marketing short-term, fixed-dose trials in bipolar mania and another indication. The clinical relevance of this finding is unknown.

The proportion of patients with CK elevations \geq 3 times ULN during a 3-week trial in pediatric bipolar 1 disorder at any time were 1%, 0%, and 1% for patients treated with asenapine 2.5 mg, 5 mg, and 10 mg twice daily, respectively, versus 3% for placebo-treated patients.

Other Adverse Reactions Observed During the Premarketing Evaluation of Asenapine:

Following is a list of MedDRA terms that reflect adverse reactions reported by patients treated with sublingual asenapine at multiple doses of \geq 5 mg twice daily during any phase of a trial within the database of adult patients. The reactions listed are those that could be of clinical importance, as well as reactions that are plausibly drug-related on pharmacologic or other grounds. Reactions already listed for adult patients in other parts of *Adverse Reactions* (6), or those considered in *Contraindications* (4), *Warnings and Precautions* (5) or *Overdosage* (10) are not included. Reactions are further categorized by MedDRA system organ class and listed in order of decreasing frequency according to the following definitions: those occurring in at least 1/100 patients (frequent) (only those not already listed in the tabulated results from placebo-controlled trials appear in this listing); those occurring in 1/100 to 1/1000 patients (infrequent); and those occurring in fewer than 1/1000 patients (rare).

Blood and lymphatic disorders: infrequent: anemia; rare: thrombocytopenia

Cardiac disorders: infrequent: temporary bundle branch block

Eye disorders: infrequent: accommodation disorder

Gastrointestinal disorders: infrequent: swollen tongue

General disorders: rare: idiosyncratic drug reaction

Investigations: infrequent: hyponatremia

Nervous system disorders: infrequent: dysarthria

Following is a list of MedDRA terms not already listed either for adults or pediatric patients in other parts of *Adverse Reactions (6)*, or those considered in *Contraindications (4)*, *Warnings and Precautions (5)* or *Overdosage (10)* that reflect adverse reactions reported by pediatric patients (Ages 10 to 17 years) treated with sublingual asenapine at doses of 2.5 mg, 5 mg, or 10 mg twice daily during any phase of a trial within the database of pediatric patients.

Eve disorders: infrequent: diplopia, vision blurred Gastrointestinal disorders: infrequent: gastroesophageal reflux disease

Injury, Poisoning, and Procedural Complications: infrequent: fall

Skin and subcutaneous tissue disorders: infrequent: photosensitivity reaction

<u>Renal and urinary disorders:</u> infrequent: enuresis_

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of asenapine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to establish a causal relationship to drug exposure. In many cases, the occurrence of these adverse reactions led to discontinuation of therapy.

- Application site reactions, primarily in the sublingual area, have been reported. These application site reactions included oral ulcers, blisters, peeling/sloughing, and inflammation.
- Choking has been reported by patients, some of whom may have also experienced oropharyngeal muscular dysfunction or hypoesthesia.

7 DRUG INTERACTIONS

7.1 Drugs Having Clinically Important Drug Interactions with Asenapine

Table 12: Clinically Important Drug Interactions with Asenapine

Concomitant Drug Name or Drug Class	Clinical Rationale	Clinical Recommendation		
Antihypertensive Drugs	Because of its α_1 -adrenergic antagonism with potential for inducing hypotension, asenapine may enhance the effects of certain antihypertensive agents [see Warnings and Precautions (5.7)].	Monitor blood pressure and adjust dosage of antihypertensive drug accordingly.		
Strong CYP1A2 Inhibitors (e.g., Fluvoxamine)	Asenapine is metabolized by CYP1A2. Marginal increase of asenapine exposure was observed when asenapine is used with fluvoxamine at 25 mg administered twice daily [see Clinical Pharmacology (12.3)]. However, the tested fluvoxamine dose was suboptimal. Full therapeutic dose of fluvoxamine is expected to cause a greater increase in asenapine exposure.	Dosage reduction for asenapine based on clinical response may be necessary.		
CYP2D6 substrates and inhibitors (e.g., paroxetine)	Asenapine may enhance the inhibitory effects of paroxetine on its own metabolism. Concomitant use of paroxetine with asenapine increased the paroxetine exposure by 2-fold as compared to use paroxetine alone [see Clinical Pharmacology (12.3)].			

7.2 Drugs Having No Clinically Important Interactions with Asenapine

No dosage adjustment of asenapine is necessary when administered concomitantly with paroxetine (see Table 12 in Drug Interactions (7.1) for paroxetine dosage adjustment), imipramine, cimetidine, valproate, lithium, or a CYP3A4 inducer (e.g., carbamazepine, phenytoin, rifampin).

In addition, valproic acid and lithium pre-dose serum concentrations collected from an adjunctive therapy study were comparable between asenapine-treated patients and placebo-treated patients indicating a lack of effect of asenapine on valproic and lithium plasma levels.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Exposure Registry

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to asenapine during pregnancy. For more information contact the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/.

Risk Summary

Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms. Studies have not been conducted with asenapine in pregnant women. There are no available human data informing the drug-associated risk. The background risk of major birth defects and miscarriage for the indicated populations are unknown. However, the background risk in the U.S. general population of major birth defects is 2 to 4% and of miscarriage is 15 to 20% of clinically recognized pregnancies. No teratogenicity was observed in animal reproduction studies with intravenous administration of asenapine to rats and rabbits during organogenesis at doses 0.7 and 0.4 times, respectively, the maximum recommended human dose (MRHD) of 10 mg sublingually twice daily. In a pre-and post-natal study in rats, intravenous administration of asenapine at doses up to 0.7 times the MRHD produced increases in post-implantation loss and early pup deaths, and decreases in subsequent pup survival and weight gain [see Data]. Advise pregnant women of the potential risk to a fetus.

Clinical Considerations

Fetal/Neonatal Adverse Reactions Extrapyramidal and/or withdrawal symptoms, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder have been reported in neonates who were exposed to antipsychotic drugs during the third trimester of pregnancy. These symptoms have varied in severity. Some neonates recovered within hours or days without specific treatment; others required prolonged hospitalization. Monitor neonates for extrapyramidal and/or withdrawal symptoms and manage symptoms appropriately.

Data Animal Data

In animal studies, asenapine increased post-implantation loss and decreased pup weight and survival at doses similar to or less than recommended clinical doses. In these studies there was no increase in the incidence of structural abnormalities caused by asenapine.

As enapine was not teratogenic in reproduction studies in rats and rabbits at intravenous doses up to 1.5 mg/kg in rats and 0.44 mg/kg in rabbits administered during organogenesis. These doses are 0.7 and 0.4 times, respectively, the maximum recommended human dose (MRHD) of 10 mg twice daily given sublingually on a mg/m² basis. Plasma levels of as enapine were measured in the rabbit study, and the area under the curve (AUC) at the highest dose tested was 2 times that in humans receiving the MRHD.

In a study in which rats were treated from day 6 of gestation through day 21 postpartum with intravenous doses of asenapine of 0.3, 0.9, and 1.5 mg/kg/day (0.15, 0.4, and 0.7 times the MRHD of 10 mg twice daily given sublingually on a mg/m² basis), increases in post-implantation loss and early pup deaths were seen at all doses, and decreases in subsequent pup survival and weight gain were seen at the two higher doses. A cross-fostering study indicated that the decreases in pup survival were largely due to prenatal drug effects. Increases in post-implantation loss and decreases in pup weight and survival were also seen when pregnant rats were dosed orally with asenapine.

8.2 Lactation

Risk Summary

Lactation studies have not been conducted to assess the presence of asenapine in human milk, the effects of asenapine on the breastfed infant, or the effects of asenapine on milk production. Asenapine is excreted in rat milk. The development and health benefits of breastfeeding should be considered along with the mother's clinical need for asenapine and any potential adverse effects on the breastfed infant from asenapine or from the underlying maternal condition.

8.4 Pediatric Use

Safety and efficacy of asenapine in pediatric patients below the age of 10 years of age have not been evaluated.

Bipolar I Disorder

The safety and efficacy of asenapine as monotherapy in the treatment of bipolar I disorder were established in a 3week, placebo-controlled, double-blind trial of 403 pediatric patients 10 to 17 years of age, of whom 302 patients received asenapine at fixed doses ranging from 2.5 mg to 10 mg twice daily [see Dosage and Administration (2.3), Adverse Reactions (6.1), Clinical Pharmacology (12.3), and Clinical Studies (14.2)]. In a Phase 1 study, pediatric patients aged 10 to 17 years appeared to be more sensitive to dystonia with initial dosing with asenapine when the recommended dose escalation schedule was not followed. Similar safety findings were reported from a 50-week, openlabel, uncontrolled safety trial in pediatric patients with bipolar I disorder treated with asenapine monotherapy. The safety and efficacy of asenapine as adjunctive therapy in the treatment of bipolar I disorder have not been established in the pediatric population. In general, the pharmacokinetics of asenapine in pediatric patients (10 to 17 years) and adults are similar [see Clinical Pharmacology (12.3)].

Juvenile Animal Data

Subcutaneous administration of asenapine to juvenile rats for 56 days from day 14 of age to day 69 of age at 0.4, 1.2, and 3.2 mg/kg/day (0.2, 0.6 and 1.5 times the maximum recommended human dose of 10 mg twice daily given sublingually on a mg/m² basis) resulted in significant reduction in body weight gain in animals of both sexes at all dose levels from the start of dosing until weaning. Body weight gain remained reduced in males to the end of treatment, however, recovery was observed once treatment ended. Neurobehavioral assessment indicated increased motor activity in animals at all dose levels following the completion of treatment, with the evidence of recovery in males. There was no recovery after the end of treatment in female activity pattern as late as day 30 following the completion of treatment (last retesting). Therefore, a No Observed Adverse Effect Level (NOAEL) for the juvenile animal toxicity of asenapine could not be determined. There were no treatment-related effects on the startle response, learning/memory, organ weights, microscopic evaluations of the brain and, reproductive performance (except for minimally reduced conception rate and fertility index in males and females administered 1.2 and 3.2 mg/kg/day).

8.5 Geriatric Use

Clinical studies of asenapine in the treatment of bipolar mania and another indication did not include sufficient numbers of patients aged 65 and over to determine whether or not they respond differently than younger patients. Of the approximately 2250 patients in pre-marketing clinical studies of asenapine, 1.1% (25) were 65 years of age or over. Multiple factors that might increase the pharmacodynamic response to asenapine, causing poorer tolerance or orthostasis, could be present in elderly patients, and these patients should be monitored carefully. Based on a pharmacokinetic study in elderly patients, dosage adjustments are not recommended based on age alone [see Clinical Pharmacology (12.3)].

Elderly patients with dementia-related psychosis treated with asenapine are at an increased risk of death compared to placebo. Asenapine is not approved for the treatment of patients with dementia-related psychosis [see Boxed Warning].

8.6 Renal Impairment

No dosage adjustment for asenapine is required on the basis of a patient's renal function (mild to severe renal impairment, glomerular filtration rate between 15 and 90 mL/minute). The exposure of asenapine was similar among subjects with varying degrees of renal impairment and subjects with normal renal function [see Clinical Pharmacology (12.3)]. The effect of renal function on the excretion of other metabolites and the effect of dialysis on the pharmacokinetics of asenapine has not been studied.

8.7 Hepatic Impairment

Asenapine is contraindicated in patients with severe hepatic impairment (Child-Pugh C) because asenapine exposure is 7-fold higher in subjects with severe hepatic impairment than the exposure observed in subjects with normal hepatic function.

No dosage adjustment for asenapine is required in patients with mild to moderate hepatic impairment (Child-Pugh A and B) because asenapine exposure is similar to that in subjects with normal hepatic function [see Contraindications (4) and Clinical Pharmacology (12.3)].

8.8 Other Specific Populations

No dosage adjustment for asenapine is required on the basis of a patient's sex, race (Caucasian and Japanese), or smoking status [see Clinical Pharmacology (12.3)].

9 DRUG ABUSE AND DEPENDENCE

9.1 Controlled Substance

Asenapine is not a controlled substance.

9.2 Abuse

Asenapine has not been systematically studied in animals or humans for its abuse potential or its ability to induce tolerance or physical dependence. Thus, it is not possible to predict the extent to which a CNS-active drug will be misused, diverted and/or abused once it is marketed. Patients should be evaluated carefully for a history of drug abuse, and such patients should be observed carefully for signs that they are misusing or abusing asenapine (e.g., drug-seeking behavior, increases in dose).

10 OVERDOSAGE


Human Experience: In adult pre-marketing clinical studies involving more than 3350 patients and/or healthy subjects, accidental or intentional acute over dosage of asenapine was identified in 3 patients. Among these few reported cases of overdose, the highest estimated ingestion of asenapine was 400 mg. Reported adverse reactions at the highest dosage included agitation and confusion.

Management of Overdosage: There is no specific antidote to asenapine. The possibility of multiple drug involvement should be considered. An electrocardiogram should be obtained and management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. Consult with a Certified Poison Control Center for up-to-date guidance and advice on the management of overdosage (1-800-222-1222.)

Hypotension and circulatory collapse should be treated with appropriate measures, such as intravenous fluids and/or sympathomimetic agents (epinephrine and dopamine should not be used, since beta stimulation may worsen hypotension in the setting of asenapineinduced alpha blockade). In case of severe extrapyramidal symptoms, anticholinergic medication should be administered. Close medical supervision and monitoring should continue until the patient recovers.

11 DESCRIPTION

Asenapine sublingual tablet contains asenapine maleate which is an atypical antipsychotic that is available for sublingual administration. Asenapine belongs to the class dibenzo-oxepino pyrroles. The chemical designation is (3aR5,12bR5)-5-Chloro-2-methyl-2,3,3a,12b-tetrahydro-1Hdibenzo[2,3:6,7]oxepino[4,5-c]pyrrole (2Z)-2 butenedioate (1:1). Its molecular formula is $C_{17}H_{16}CINO-C_4H_4O_4$ and its molecular weight is 401.84 (free base: 285.8). The chemical structure is:



Asenapine maleate is off-white to white powder.

Asenapine is supplied for sublingual administration in tablets containing 2.5-mg, 5-mg or 10-mg asenapine; inactive ingredients include povidone, butylated hydroxy toluene, butylated hydroxy anisole, mannitol, low-substituted hydroxypropyl cellulose, sodium stearyl furmarate.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The mechanism of action of asenapine in bipolar I disorder is unknown.

12.2 Pharmacodynamics

Asenapine exhibits high affinity for serotonin 5-HT_{1A}, 5-HT_{1B}, 5-HT_{2A}, 5-HT_{2B}, 5-HT_{2C}, 5-HT_{5A}, 5-HT₆, and 5-HT₇ receptors (Ki values of 2.5, 2.7, 0.07, 0.18, 0.03, 1.6, 0.25, and 0.11 nM, respectively), dopamine D_{2A}, D_{2B}, D₃, D₄, and D₁ receptors (Ki values of 1.3, 1.4, 0.42, 1.1, and 1.4 nM, respectively), α_{1A} , α_{2A} , α_{2B} , and α_{2C} -adrenergic receptors (Ki values of 1.2, 1.2, 0.33 and 1.2 nM, respectively), and histamine H₁ receptors (Ki value 1 nM), and moderate affinity for H₂ receptors. Asenapine has no appreciable affinity for muscarinic cholinergic receptors (e.g., Ki value of 8128 nM for M₁).

12.3 Pharmacokinetics

Following a single 5 mg dose of asenapine, the mean C_{max} was approximately 4 ng/mL and was observed at a mean t_{max} of 1 hour. Elimination of asenapine is primarily through direct glucuronidation by UGT1A4 and oxidative metabolism by cytochrome P450 isoenzymes (predominantly CYP1A2). Following an initial more rapid distribution phase, the mean terminal half-life is approximately 24 hrs. With multiple-dose twice-daily dosing, steady-state is attained within 3 days. Overall, steady-state Asenapine pharmacokinetics.

peak plasma concentrations occurring within 0.5 to 1.5 hours. The absolute bioavailability of sublingual asenapine at 5 mg is 35%. Increasing the dose from 5 mg to 10 mg twice daily (a two-fold increase) results in less than linear (1.7 times) increases in both the extent of exposure and maximum concentration. The absolute bioavailability of asenapine when swallowed is low (<2% with an oral tablet formulation).

The intake of water several (2 or 5) minutes after asenapine administration resulted in decreased asenapine exposure. Therefore, eating and drinking should be avoided for 10 minutes after administration [see Dosage and Administration (2.1)].

Distribution: As enapine is rapidly distributed and has a large volume of distribution (approximately 20 to 25 L/kg), indicating extensive extravascular distribution. As enapine is highly bound (95%) to plasma proteins, including albumin and $\alpha_1\text{-acid glycoprotein.}$

Metabolism and Elimination: Direct glucuronidation by UGT1A4 and oxidative metabolism by cytochrome P450 isoenzymes (predominantly CYP1A2) are the primary metabolic pathways for asenapine.

Asenapine is a high clearance drug with a clearance after intravenous administration of 52 L/h. In this circumstance, hepatic clearance is influenced primarily by changes in liver blood flow rather than by changes in the intrinsic clearance, i.e., the metabolizing enzymatic activity. Following an initial more rapid distribution phase, the terminal half-life of asenapine is approximately 24 hours. Steady-state concentrations of asenapine are reached within 3 days of twice daily dosing.

After administration of a single dose of [¹⁴C]-labeled asenapine, about 90% of the dose was recovered; approximately 50% was recovered in urine, and 40% recovered in feces. About 50% of the circulating species in plasma have been identified. The predominant species was asenapine N⁺-glucuronide; others included N-desmethylasenapine, N-desmethylasenapine N-carbamoyl glucuronide, and unchanged asenapine in smaller amounts. Asenapine activity is primarily due to the parent drug.

In vitro studies indicate that asenapine is a substrate for UGT1A4, CYP1A2 and to a lesser extent CYP3A4 and CYP2D6. Asenapine is a weak inhibitor of CYP2D6. Asenapine does not cause induction of CYP1A2 or CYP3A4 activities in cultured human hepatocytes. Coadministration of asenapine with known inhibitors, inducers or substrates of these metabolic pathways has been studied in a number of drug-drug interaction studies [see Drug Interactions (7.1)].


Food: A crossover study in 26 healthy adult male subjects was performed to evaluate the effect of food on the pharmacokinetics of a single 5 mg dose of asenapine. Consumption of food immediately prior to sublingual administration decreased asenapine exposure by 20%; consumption of food 4 hours after sublingual administration decreased asenapine exposure by about 10%. These effects are probably due to increased hepatic blood flow.

In clinical trials establishing the efficacy and safety of asenapine, patients were instructed to avoid eating for 10 minutes following sublingual dosing. There were no other restrictions with regard to the timing of meals in these trials [see Dosage and Administration (2.1)].

Water: In clinical trials establishing the efficacy and safety of asenapine, patients were instructed to avoid drinking for 10 minutes following sublingual dosing. The effect of water administration following 10 mg sublingual asenapine dosing was studied at different time points of 2, 5, 10, and 30 minutes in 15 healthy adult male subjects. The exposure of asenapine following administration of water 10 minutes after sublingual dosing. Reduced exposure to asenapine was observed following water administration at 2 minutes (19% decrease) and 5 minutes (10% decrease) *[see Dosage and Administration (2.1)]*.

Drug Interaction Studies:


Effects of other drugs on the exposure of asenapine are summarized in Figure 1. In addition, a population pharmacokinetic analysis indicated that the concomitant administration of lithium had no effect on the pharmacokinetics of asenapine. Figure 1: Effect of Other Drugs on Asenapine Pharmacokinetics



*: When a low dose of 25 mg twice daily fluvosamine was co-administered with asenapine, a 29% increase in asenapine exposure was observed. Concomitant use of a therapeutic dose of fluvoxamine may cause greater increases in asenapine exposure.

The effects of asenapine on the pharmacokinetics of other co-administered drugs are summarized in Figure 2. Coadministration of paroxetine with asenapine caused a two-fold increase in the maximum plasma concentrations and systemic exposure of paroxetine. Asenapine enhances the inhibitory effects of paroxetine on its own metabolism by CYP2D6.

Figure 2: Effect of Asenapine on Other Drug Pharmacokinetics



*: Asenapine may enhance the inhibitory effects of paroxetine on its own metabolism

¹ to two, Asenapine appears to be at most a weak inhittor of CYP2D6. Following coadministration of dextromethorphan and asenapine in healthy subjects, the ration of destrorphan/destromethorphan (DX/DM) as a marker of CYP2D6 activity was measured. Indicative of CYP2d6 inhibition, tratement with asenapine 5 mg twice daily decreased the DX/DM ratio to 0.43. In the same study, treatment with paroxetine 20 mg daily decreased the DX/DM ratio to 0.032. In a separate study, coadministration of a singly 75 mg dose of impiramine with a singly 5 mg dose of asenapine did not affect the plasma concentrations, of the metabolite desipramine (a CYP2D6 substrate).

Studies in Special Populations:

Exposures of asenapine in special populations are summarized in Figure 3. Additionally, based on population pharmacokinetic analysis, no effects of sex, race, BMI, and smoking status on asenapine exposure were observed. Exposure in elderly patients is 30 to 40% higher as compared to adults.

Figure 3: Effect of Intrinsic Factors on Asenapine Pharmacokinetics

rigure 5. Effect of finality		ASC	apine	Filain	aconi	leucs	
Population Description	PK		Fold (Change	and 9	90% C	
RENAL IMPAIRED-Mild	Cmax	K	H				
	AUC						
RENAL IMPAIRED-Moderate	Cmax	ł	÷I –				
	AUC						
RENAL IMPAIRED-Severe	Cmax		•				
	AUC	,	¢I				
HEPATIC IMPAIRED-Mild	Cmax	K	н				
	AUC	ŀ	♦ 1				
HEPATIC IMPAIRED-Moderate	Cmax						
	AUC	ŀ	♦-				
HEPATIC IMPAIRED-Severe	Cmax	۲	н —				
	AUC			H	+		
SMOKER	Cmax	•	•				
	AUC		*				
JAPANESE	Cmax	ŀ	♦ 1				
	AUC	1	₽ I				
		_					_
		0	2	4	6	8	10
			Chang	e relativ	ve to re	ference	
			-				

The data shown for renal and hepatic impairment are relative to subjects with normal renal and hepatic function, respectively.

The data shown for smoker are relative to non-smoker.

The data shown for Japanese are relative to Caucasian.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis: In a lifetime carcinogenicity study in CD-1 mice asenapine was administered subcutaneously at doses up to those resulting in plasma levels (AUC) estimated to be 5 times those in humans receiving the MRHD of 10 mg twice daily. The incidence of malignant lymphomas was increased in female mice, with a no-effect dose resulting in plasma levels estimated to be 1.5 times those in humans receiving the MRHD. The mouse strain used has a high and variable incidence of malignant lymphomas, and the significance of these results to humans is unknown. There were no increases in other tumor types in female mice. In male mice, there were no increases in any tumor type.

In a lifetime carcinogenicity study in Sprague-Dawley rats, asenapine did not cause any increases in tumors when administered subcutaneously at doses up to those resulting in plasma levels (AUC) estimated to be 5 times those in humans receiving the MRHD.

Mutagenesis: No evidence for genotoxic potential of asenapine was found in the *in vitro* bacterial reverse mutation assay, the *in vitro* forward gene mutation assay in mouse lymphoma cells, the *in vitro* chromosomal aberration assays in human lymphocytes, the *in vitro* sister chromatid exchange assay in rabbit lymphocytes, or the *in vivo* micronucleus assay in rats.

Impairment of Fertility: As enapine did not impair fertility in rats when tested at doses up to 11 mg/kg twice daily given orally. This dose is 10 times the maximum recommended human dose of 10 mg twice daily given sublingually on a mg/m² basis.

14 CLINICAL STUDIES

Efficacy of asenapine was established in the following trials:

- One fixed-dose, short term trial of monotherapy in children (10 to 17 years) with manic or mixed episodes associated with bipolar I disorder [see Clinical Studies (14.2)]
- One flexible-dose, short-term trial in adult patients with manic or mixed episode associated with bipolar I disorder as adjunctive treatment to lithium or valproate [see Clinical Studies (14.2)]

14.2 Bipolar I Disorder

Monotherapy

Pediatric patients: The efficacy of asenapine in the treatment of acute mania was established in a single, 3-week, placebo-controlled, double-blind trial of 403 pediatric patients 10 to 17 years of age, of whom 302 patients received asenapine at fixed doses of 2.5 mg, 5 mg and 10 mg twice daily. All patients were started on 2.5 mg twice daily. For those assigned to 5 mg twice daily, the dose was increased to 5 mg twice daily after 3 days. For those assigned to 10 mg twice daily, the dose was increased from 2.5 to 5 mg twice daily after 3 days. For those assigned to 10 mg twice daily ther 3 additional days.

Asenapine was statistically superior to placebo in improving YMRS total score and the CGI-BP Severity of Illness overall score as measured by the change from baseline to week 3 (Trial 3 Pediatric in Table 14). An examination of subgroups did not reveal any clear evidence of differential responsiveness on the basis of age, sex, and race.

Adjunctive Therapy: The efficacy of asenapine as an adjunctive therapy in acute mania was established in a 12-week, placebo-controlled trial with a 3-week primary efficacy endpoint involving 326 adult patients with a manic or mixed episode of Bipolar 1 Disorder, with or without psychotic features, who were partially responsive to lithium or valproate monotherapy after at least 2 weeks of treatment. All patients randomized to asenapine were initially administered 5 mg twice daily, and the dose could be adjusted within the dose range of 5 to 10 mg twice daily superior to placebo in the reduction of manic symptoms (measured by the YMRS total score) as an adjunctive therapy to lithium or valproate monotherapy at week 3 (Trial 5 Adjunctive in Table 14).

Table 14: Acute Bipolar I Trials Establishing Efficacy in Adults and Pediatric Patients 10 to 17 Years

Study Number	Treatment Group	Primary Efficacy Measure: YMRS Total Score			
		Mean Baseline Score (SD)	LS Mean Change from Baseline (SE)	Placebo- subtracted Difference ^a (95% Cl)	
Trial 4 (Pediatric 10 to 17	Asenapine 2.5 mg* twice daily	29.5 (5.7)	-12.8 (0.8)	-3.2 (-5.6, - 0.8)	
/ears)	Asenapine 5 mg* twice daily	30.4 (5.9)	-14.9 (0.8)	-5.3 (-7.7, - 2.9)	
	Asenapine 10 mg* twice daily	30.1 (5.7)	15.8 (0.9)	-6.2 (-8.6, - 3.8)	
	Placebo	30.1 (5.7)	-9.6 (0.9)		
Trial 5 (Adjunctive)	Asenapine 5 to 10 mg* twice daily + Lithium/Valproate	28 (5.6)	-10.3 (0.8)	-2.4 (-4.4, - 0.3)	
	Lithium/Valproate	28.2 (5.8)	-7.9 (0.8)		

SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: confidence interval, not adjusted for multiple comparisons.

^a Difference (drug minus placebo) in least-squares mean change from baseline.

* Doses that are demonstrated to be effective.

16 HOW SUPPLIED/STORAGE AND HANDLING

Asenapine sublingual tablets are supplied as:

2.5 mg Tablets: White to off white, round tablets debossed with 'L' on one side and '70' on the other side.

Cartons of 60 - 6 blister cards of 10 tablets each NDC 62332-544-60 Cartons of 100 - 10 blister cards of 10 tablets each NDC 62332-544-31

5-mg Tablets: White to off white, round tablets debossed with "464" on one side and plain on other side.

Cartons of 60 - 6 blister cards of 10 tablets each NDC 62332-198-60 Cartons of 100 - 10 blister cards of 10 tablets each NDC 62332-198-31

 ${\bf 10\text{-}mg}\ {\bf Tablets:}$ White to off white, round tablets debossed with "465" on one side and plain on other side.

Cartons of 60 - 6 blister cards of 10 tablets each NDC 62332-199-60 Cartons of 100 - 10 blister cards of 10 tablets each NDC 62332-199-31

Storage

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Instructions for Use).

Dosage and Administration

Counsel patients on proper sublingual administration of asenapine and advise them to read the FDA-approved patient labeling (Instructions for Use). When initiating treatment with asenapine, provide dosage escalation instructions [see Dosage and Administration (2)].

Hypersensitivity Reactions

Counsel patients on the signs and symptoms of a serious allergic reaction (e.g., difficulty breathing, itching, swelling of the face, tongue or throat, feeling lightheaded etc.) and to seek immediate emergency assistance if they develop any of these signs and symptoms [see Contraindications (4), Warnings and Precautions (5.6) and Adverse Reactions (6)].

Application Site Reactions

Inform patients that application site reactions, primarily in the sublingual area, including oral ulcers, blisters, peeling/sloughing and inflammation have been reported. Instruct patients to monitor for these reactions [see Adverse Reactions (6.2)]. Inform patients that numbness or tingling of the mouth or throat may occur directly after administration of asenapine and usually resolves within 1 hour [see Adverse Reactions (6.1)].

Neuroleptic Malignant Syndrome

Counsel patients about a potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) that has been reported in association with administration of antipsychotic drugs. Patients should contact their health care provider or report to the emergency room if they experience the following signs and symptoms of NMS, including hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia) *[see Warnings and Precautions (5.3)].*

Tardive Dyskinesia

Counsel patients on the signs and symptoms of tardive dyskinesia and to contact their health care provider if these abnormal movements occur [see Warnings and Precautions (5.4)].

Metabolic Changes (Hyperglycemia and Diabetes Mellitus, Dyslipidemia, and Weight Gain)

Educate patients about the risk of metabolic changes, how to recognize symptoms of hyperglycemia (high blood sugar) and diabetes mellitus, and the need for specific monitoring, including blood glucose, lipids, and weight [see Warnings and Precautions (5.5)].

Orthostatic Hypotension

Educate patients about the risk of orthostatic hypotension (symptoms include feeling dizzy or lightheaded upon standing) especially early in treatment, and also at times of reinitiating treatment or increases in dose [see Warnings and Precautions (5.7)].

Leukopenia/Neutropenia

Advise patients with a pre-existing low WBC or a history of drug induced leukopenia/neutropenia they should have their CBC monitored while taking asenapine [see Warnings and Precautions (5.9)].

Hyperprolactinemia

Counsel patients on the signs and symptoms of hyperprolactinemia and to contact their health care provider if these abnormalities occur [see Warnings and Precautions (5.11)].

Interference with Cognitive and Motor Performance

Caution patients about performing activities requiring mental alertness, such as operating hazardous machinery or operating a motor vehicle, until they are reasonably certain that asenapine therapy does not affect them adversely [see Warnings and Precautions (5.13)].

Heat Exposure and Dehydration

Counsel patients regarding appropriate care in avoiding overheating and dehydration [see Warnings and Precautions (5.14)].

Concomitant Medications

Advise patients to inform their health care provider if they are taking, or plan to take, any prescription or over-the-counter medications since there is a potential for interactions [see Drug Interactions (7.1)].

Pregnancy

Advise patients that asenapine may cause fetal harm as well as extrapyramidal and/or withdrawal symptoms in a neonate. Advise patients to notify their healthcare provider with a known or suspected pregnancy [see Use in Specific Populations (8.1)].

Pregnancy Registry

Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to asenapine during pregnancy [see Use in Specific Populations (8.1)].

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Manufactured by: Alembic Pharmaceuticals Limited (Formulation Division),

Panelav 389350, Gujarat, India

Manufactured for: Alembic Pharmaceuticals, Inc. Bedminster, NJ 07921, USA

Revised: 07/2021

INSTRUCTIONS FOR USE Asenapine (a-SEN-a-peen) Sublingual Tablets

Read these Instructions for Use before you start using asenapine sublingual tablets and each time you get a refill. There may be new information. This leaflet does not take the place of talking to your doctor about your medical condition or your treatment.

IMPORTANT:

•For sublingual (under your tongue) use only. •Do not remove tablet until ready to administer. •Use dry hands when handling tablet.

Yourasenapine sublingual tablets



Directions for Taking your Asenapine Sublingual Tablets: Step 1. Firmly press and hold thumb button, then pull out the tablet pack (see Figure A). Do not push tablet through the tablet pack. Do not cut or tear the tablet




Figure A

Step 2. Peel off the lidding foil carefully. (see Figure B).



Figure B

Step 3. Gently remove the tablet (see Figure C). Do not split, cut or crush the tablet.



Step 4. Place the whole tablet under tongue and allow it to dissolve completely (see Figure D).



Figure D Do not chew or swallow the tablet. Do not eat or drink for 10 minutes (See Figure E).



Figure E ${\bf Step 5.}$ Slide the tablet pack back into case until it clicks (see Figure F).



Figure F **Storing asenapine sublingual tablets:** Store asenapine sublingual tablets at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F).

These Instructions for Use have been approved by the U.S. Food and Drug Administration.

For more information call 1-866-210-9797.

Manufactured by: Alembic Pharmaceuticals Limited (Formulation Division), Panelav 389350, Gujarat, India


Manufactured for: Alembic Pharmaceuticals, Inc. Bedminster, NJ 07921, USA

Revised: 07/2021

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL 2.5 mg


NDC 62332-544-60 Asenapine Sublingual Tablets 2.5 mg For sublingual (under the tongue) use only. Do not split, cut or crush tablet. Do not chew or swallow tablet. Fragile: Do not push tablet through tablet pack. Rx only

Alembic 60 Tablets - 6 blister cards of 10 tablets each



PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 5 mg


NDC 62332-198-60 Asenapine Sublingual Tablets 5 mg For sublingual (under the tongue) use only. Do not split, cut or crush tablet. Do not chew or swallow tablet. Fragile: Do not push tablet through tablet pack Rx only Alembic 60 Tablets - 6 blister cards of 10 tablets each



PACKAGE LABEL.PRINCIPAL DISPLAY PANEL 10 mg NDC 62332-199-60 Asenapine Sublingual Tablets 10 mg For sublingual (under the tongue) use only. Do not split, cut or crush tablet. Do not chew or swallow tablet. Fragile: Do not push tablet through tablet pack Rx only

Fragile: Do not push tablet through tablet pack Rx only Alembic

60 Tablets - 6 blister cards of 10 tablets each



ASENAPINE					
asenapine tablet					
Product Information					
Product Type	HUMAN PRESCRIPTION DRUG	ltem (Code (Source)	NDO	2:62332-544
Route of Administration	SUBLINGUAL				
Active Ingredient/Active	Moiety				
•	e Moiety dient Name		Basis of Stren	igth	Strength
Ingre	dient Name	,	Basis of Stren	ıgth	Strength 2.5 mg
Ingre	dient Name			igth	-
Active Ingredient/Active Ingre ASENAPINE (UNII: JKZ 19V9080) (Inactive Ingredients	dient Name	, ,		igth	Strength 2.5 mg

	VIDONE K30 (L					
			(UNII: 1P9D0Z171K) (UNII: REK4960K2U)			
MANNITOL (UNII: 30WL53L36A) HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED (UNII: 2165RE0K14)						
			INII: 7CV7WJK4UI)	0614)		
Pı	oduct Char	acteristics				
	lor		to off white)	Score	no score	
	ape avor	ROUND		Size Imprint Code	4mm L;70	
	ntains			Imprint code	2,70	
Pa	ackaging					
#	Item Code	m Code Package Description		Marketing Start Date	Marketing End Date	
	NDC:62332-	60 in 1 CARTO	N	07/20/2021	Date	
	544-60 NDC:62332-		R PACK; Type 0: Not a Combination	0772072021		
-	544-10 NDC:62332-	Product				
2	544-31	100 in 1 CART(07/20/2021		
2		10 in 1 BLISTE Product	R PACK; Type 0: Not a Combination			
	arkoting	Informat	ion			
I	Marketing		tion Number or Monograph	Marketing Start	Marketing End	
	Category		Citation	Date	Date	
AN	DA	ANDA20609	8	07/20/2021		
49	SENAPINE					
ase	enapine table	t				
	roduct Infoi oduct Type	mation	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:62332-198	
	oute of Admin	istration	SUBLINGUAL	item code (source)	NDC.02332-198	
	ate of Admin	istration	SOBEINGOILE			
A	tive Ingred		Molety lient Name	Basis of Stre	ngth Strength	
AS	ENAPINE (UNII:	-	SENAPINE - UNII:JKZ19V9080)	ASENAPINE	5 mg	
In	active Ingre	dients				
			Ingredient Name		Strength	
	VIDONE K30 (L		2X) (UNII: 1P9D0Z171K)			
			(UNII: REK4960K2U)			
	ANNITOL (UNII: 3					
			LOW SUBSTITUTED (UNII: 2165RE INII: 7CV7WJK4UI)	UK14)		
D,	oduct Char	actoristics				
	lor		to off white)	Score	no score	
	ape	ROUND		Size	6mm	
	avor Intains			Imprint Code	464	
D -						
	ackaging	_		Marketing Start	Marketing End	
#	Item Code	Pa	ckage Description	Date	Date	
	NDC:62332- 198-60	60 in 1 CARTO	N	12/10/2020		
1	NDC:62332- 198-10	10 in 1 BLISTE Product	R PACK; Type 0: Not a Combination			
2	NDC:62332-	100 in 1 CARTO	2N	12/10/2020		
2	198-31	10 in 1 BLISTE	R PACK; Type 0: Not a Combination			
-		Product				
м	arketing	Informat	ion			
	Marketing	Applica	tion Number or Monograph	Marketing Start	Marketing End	
AN	Category DA	ANDA20609	Citation 8	Date 12/10/2020	Date	
	SENAPINE					
20	ananine takla					
ase	enapine table	t				
	enapine table roduct Infoi					
P			HUMAN PRESCRIPTION DRUG	ltem Code (Source)	NDC:62332-199	
P Pr	roduct Info	rmation	HUMAN PRESCRIPTION DRUG SUBLINGUAL	Item Code (Source)	NDC:62332-199	

Active Ingredient/Active Moiety						
Ingredient Name	Basis of Strength	Strength				
ASENAPINE (UNII: JKZ 19V9080) (ASENAPINE - UNII: JKZ 19V9080)	ASENAPINE	10 mg				
Inactive Ingredients						
Ingredient Name		Strength				
POVIDONE K30 (UNII: U725QWY32X)						

BUTYLATED HYDROXYTOLUENE (UNII: 1P9D0Z171K)

SODIUM STEARY	FUMARATE (UNII: 7CV7WK4UI)		
Product Char	acteristics		
Color WHITE (White to off white)		Score	no score
Shape	ihape ROUND Size		8mm
Flavor		Imprint Code	465
Contains			
Packaging			
# Item Code	Package Description	Marketing Start Date	Marketing End Date
1 NDC:62332- 199-60	60 in 1 CARTON	12/10/2020	
1 NDC:62332- 199-10 Product 10 in 1 BLISTER PACK; Type 0: Not a Combination			
NDC:62332- 199-31 100 in 1 CARTON		12/10/2020	
	10 in 1 BLISTER PACK; Type 0: Not a Combination		
2 199-31	Product		
2 199-31 2	Product		
2 199-31 2		Marketing Start Date	Marketing End Date

Labeler - Alembic Pharmaceuticals Inc. (079288842)

Establishment					
Name	Address	ID/FEI	Business Operations		
Alembic Pharmaceuticals Limited		650574671	MANUFACTURE(62332-198, 62332-199, 62332-544)		

Revised: 9/2021 Alembic Pharmaceuticals Inc.